Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile (CLIN01)

Phillip Brian Smith

Status and phase: Completed; Phase 1

Conditions: Obesity; Bacterial Infections

Treatments: Drug: Clindamycin

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT01744730

Pro00041855

HHSN275201000003I (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to better understand how clindamycin works in children who fall in the 85th percentile or higher for body mass index (BMI - a ratio of weight to height). The results of the study will help better understand if children in higher BMI ranges process the medication differently and whether dosing should be adjusted in these children.

Full description

This is a prospective, open-label pharmacokinetic and safety study of multiple doses of IV and oral clindamycin in overweight and obese children ages 2 to 17 years of age. The total study duration is expected to be approximately 24 months; each subject will participate in the study for up to 18 days (screening day; treatment days 1-14 [may be as short as 2 days] followed by an observation period of 3 days post discontinuation of clindamycin therapy or after day 17 (on day 18) of therapy in those who are treated with more than 14 days of clindamycin).

Enrollment: 22 patients

Sex: All

Ages: 2 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 2 years - < 18 years of age at the time of first dose of study drug
• Suspected or confirmed infection OR receiving IV clindamycin per routine care
• Negative serum pregnancy test (if female and has reached menarche) within 24 hours of first dose of study drug and agreement to practice appropriate contraceptive measures, including abstinence, from the time of the initial pregnancy test through the last dose of study drug
• BMI ≥ 85th percentile for age and sex, based on Centers for Disease Control (CDC) recommendations
• Signed informed consent/Health Insurance Portability and Accountability Act (HIPAA) documents by the parent/legal guardian and assent (if applicable)

Exclusion criteria

• The following apply only to those who are NOT already receiving clindamycin per routine care:

  1. History of hypersensitivity or allergic reaction to clindamycin or lincomycin
  2. History of C. difficile colitis with previous administration of clindamycin
  3. Aspartate aminotransferase (AST) > 120 units/L
  4. Alanine aminotransferase (ALT) > 210 units/L
  5. Total bilirubin > 3 mg/dL
  6. Serum creatinine > 2 mg/dL
  7. Receiving a neuromuscular blocker as part of their therapy

• Previous participation in the study

• Subject is on prohibited medication or herbal product (see Appendix II)

• Subject is receiving extracorporeal life support (ECLS)

• Subject is post-cardiac bypass (within 24 hours)

• Subject on inotropes/pressors

• Any other condition or chronic illness that, in the opinion of the principal investigator, makes participation unadvised or unsafe

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

22 participants in 4 patient groups

Clindamycin IV-ages 2 to 11 Years Old (BMI 85-95th Percentile)

Active Comparator group

Description:

Clindamycin IV: Children ages 2 to 11 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.

Treatment:

Drug: Clindamycin

Clindamycin IV-ages 2 to 11 Years Old (BMI Greater Than 95th)

Active Comparator group

Description:

Clindamycin IV: Children ages 2 to 11 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.

Treatment:

Drug: Clindamycin

Clinidamycin IV-ages 12 to 17 (BMI 85-95th Percentile)

Active Comparator group

Description:

Clindamycin IV: Children ages 12 to 17 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.

Treatment:

Drug: Clindamycin

Clindamycin IV-ages 12 to 17 (BMI Greater Than 95th)

Active Comparator group

Description:

Clindamycin IV: Children ages 12 to 17 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.

Treatment:

Drug: Clindamycin